Search results for "Docetaxel"

showing 6 items of 116 documents

Arterial Stiffness: Effects of Anticancer Drugs Used for Breast Cancer Women

2021

Purpose: It is well known that anticancer drugs used for treating breast cancer can cause cardiac toxicity, and less is known about vascular toxicity. The aim of this study was to assess subclinical vascular effects of anthracyclines and trastuzumab (TRZ) in women treated for breast cancer.Methods: We enrolled 133 female patients with breast cancer undergoing adjuvant treatment with anthracycline-containing chemotherapy (CT) followed by taxane (paclitaxel/docetaxel) + TRZ. Patients underwent a standard echocardiography including measurement of left ventricular ejection fraction and global longitudinal strain at baseline and at follow-up. Vascular toxicity was evaluated by measuring brachial…

medicine.medical_specialtyAnthracyclinePhysiologypulse wave velocitycardiotoxicity030204 cardiovascular system & hematologychemotherapy03 medical and health sciences0302 clinical medicineBreast cancerInternal medicinePhysiology (medical)medicineQP1-981Pulse wave velocityvascular injuryOriginal ResearchTaxaneEjection fractionbusiness.industrymedicine.diseaseArterial stiffneBlood pressurearterial stiffness; cardiotoxicity; chemotherapy; pulse wave velocity; vascular injuryarterial stiffnessDocetaxel030220 oncology & carcinogenesisCardiologyArterial stiffnessbusinessmedicine.drugFrontiers in Physiology
researchProduct

Docetaxel as Salvage Therapy in Highly Pretreated and Drug Resistant Gastrointestinal Carcinomas

2008

Introduction Despite many efforts to develop new chemotherapies for metastatic upper gastrointestinal (GI) cancer, overall prognosis continues to be fatal, particularly in gastric and pancreatic cancer. Many of these patients deserve second-or third-line treatment after failure of first-line chemotherapy. Therefore, we analysed toxicity and response rate of weekly docetaxel after failed upfront regimes in these upper GI cancer patients. Patients and Methods Between 2001 and 2006, 18 patients received docetaxel based regimes (35 mg/m2 weekly) after informed consent. Response rates were determined using RECIST criteria or tumor progression if clinically evident. Toxicities were graded based o…

medicine.medical_specialtyPathologymedicine.medical_treatmentSalvage therapyNeutropeniachemotherapygastriclcsh:RC254-282GastroenterologysalvageInternal medicinePancreatic cancermedicinedocetaxelOriginal ResearchChemotherapyLeukopeniabusiness.industryCancerlcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensmedicine.diseasemetastaticRegimenOncologyDocetaxelmedicine.symptombusinessmedicine.drugClinical medicine. Oncology
researchProduct

Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epiru…

2019

Background Docetaxel-based chemotherapy is effective in metastatic gastric and gastro-oesophageal junction adenocarcinoma. This study reports on the safety and efficacy of the docetaxel-based triplet FLOT (fluorouracil plus leucovorin, oxaliplatin and docetaxel) as a perioperative therapy for patients with locally advanced, resectable tumours. Methods In this controlled, open-label, phase 2/3 trial, we randomly assigned 716 patients with histologically-confirmed advanced clinical stage cT2 or higher or nodal positive stage (cN+), or both, resectable tumours, with no evidence of distant metastases, via central interactive web-based-response system, to receive either three pre-operative and t…

medicine.medical_specialtyeducation.field_of_studyChemotherapybusiness.industrymedicine.medical_treatmentPopulationMedizinGeneral MedicinePerioperative030204 cardiovascular system & hematologyGastroenterologyOxaliplatinCapecitabine03 medical and health sciences0302 clinical medicineDocetaxelFluorouracilInternal medicineMedicine030212 general & internal medicinebusinesseducationmedicine.drugEpirubicinThe Lancet
researchProduct

Cytotoxicity of natural products and derivatives toward MCF-7 cell monolayers and cancer stem-like mammospheres

2015

Abstract Although cancer stem-like cells (CSCs) are rare, they can enter a non-proliferative or dormant state and resist therapy. Furthermore, quiescent CSCs are responsible for metastases that can appear after curative surgical treatment of a primary tumor. Because of drug resistance of CSCs, the development of novel therapies is urgently required that specifically target CSCs. Purpose The aim of the present study was to investigate the potential of a panel of natural products and derivatives to inhibit CSC-enriched mammospheres of MCF-7 breast cancer cells. Methods CD44high/CD24low cells were identified by flow cytometry and maintained as mammospheres. As a control, we used two clinically…

medicine.medical_treatmentPhytochemicalsCellArtesunatePharmaceutical ScienceAntineoplastic AgentsBiologyPharmacologyFlow cytometrySpheroids CellularStilbenesDrug DiscoverymedicineHumansCytotoxicityPharmacologyChemotherapymedicine.diagnostic_testCancermedicine.diseasePrimary tumorArtemisininsSalicylatesmedicine.anatomical_structureComplementary and alternative medicineDocetaxelMCF-7MCF-7 CellsNeoplastic Stem CellsMolecular MedicineNaphthoquinonesmedicine.drugPhytomedicine
researchProduct

Effects of ectopic expression of NGAL on doxorubicin sensitivity.

2012

Neutrophil gelatinase-associated lipocalin (NGAL, a.k.a Lnc2) is a member of the lipocalin family which has diverse roles including stabilizing matrix metalloproteinase-9 from auto-degradation and as siderocalins which are important in the transport of iron. NGAL also has important biological functions involved in immunity and inflammation as well as responses to kidney damage. NGAL expression has also been associated with certain neoplasia and is important in the metastasis of breast cancer. Many advanced cancer patients have elevated levels of NGAL in their urine and it has been proposed that NGAL may be a prognostic indicator for certain cancers (e.g. breast, brain, and others). NGAL exp…

siderocalinColorectal cancerBlotting WesternResistanceBreast NeoplasmsLipocainBiologyLipocalinsiderocalinsMetastasisBreast cancerLcn2Lipocalin-2Proto-Oncogene ProteinsmedicineTumor Cells CulturedHumansDoxorubicinNGALIron transportCell Proliferationdrug resistanceAntibiotics AntineoplasticCancermedicine.diseaseResearch PapersLipocalinsOncologyDocetaxelDrug Resistance NeoplasmDoxorubicinImmunologyCancer researchDoxorubicin; Drug resistance; Iron transport; Lcn2; Lipocalins; MMP-9; NGAL; SiderocalinsEctopic expressionFemalelipocalinMMP-9Colorectal Neoplasmsmedicine.drugAcute-Phase Proteins
researchProduct

Estudio farmacogenético del tratamiento del cáncer de mama basado en antraciclinas y taxanos

2016

Existe una importante variabilidad interindividual en la respuesta a los medicamentos que condiciona que no sea fácil predecir la efectividad o seguridad de un fármaco en un paciente concreto. La Farmacogenética (PGt) estudia el vínculo entre las variaciones en la secuencia de ADN de un paciente y su respuesta al tratamiento farmacológico. La variación de un único nucleótido puede tener consecuencias dramáticas, de modo que la identificación de variantes que alteren la función o expresión de las proteínas implicadas en la farmacocinética o farmacodinamia y su efecto final sobre la respuesta es el objetivo de la PGt. El Cáncer de Mama (CM) es el tipo de cáncer más frecuente en mujeres. A pes…

taxanosantraciclinas:CIENCIAS DE LA VIDA::Genética [UNESCO]doxorubicina:CIENCIAS MÉDICAS ::Farmacología [UNESCO]SNPreacción adversa:CIENCIAS MÉDICAS ::Ciencias clínicas::Oncología [UNESCO]UNESCO::CIENCIAS MÉDICAS ::Farmacodinámica::QuimioterapiapolimorfismoepirubicinaUNESCO::CIENCIAS MÉDICAS ::FarmacologíafarmacogenéticapaclitaxelUNESCO::CIENCIAS MÉDICAS ::Ciencias clínicas::OncologíaUNESCO::CIENCIAS DE LA VIDA::Genéticacáncermama:CIENCIAS MÉDICAS ::Farmacodinámica::Quimioterapia [UNESCO]docetaxeltoxicidadantineoplásicoquimioterapia
researchProduct